Related Experiment Videos
Serum lipid levels in hypertensive patients during captopril treatment
T Nishide1, K Shirai, M Shinomiya
1Second Department of Internal Medicine, School of Medicine, Chiba University, Japan.
Insights
Captopril effectively lowers blood pressure in hypertensive patients without negatively impacting serum lipoprotein metabolism or lipid levels. Some patients with unfavorable lipid profiles showed improvements.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Studies
Background:
- Hypertension is a significant risk factor for cardiovascular disease.
- Angiotensin-converting enzyme (ACE) inhibitors, like captopril, are commonly used to manage hypertension.
- The potential impact of antihypertensive medications on lipid metabolism requires careful evaluation.
Purpose of the Study:
- To assess the effect of captopril on blood pressure and serum lipid profiles in hypertensive patients.
- To determine if captopril influences total cholesterol, triglycerides, lipoprotein cholesterol, and apolipoproteins.
- To evaluate changes in the atherogenic index and identify any specific patient subgroups that might benefit in terms of lipid levels.
Main Methods:
- A 16-week open-label study involving 64 hypertensive patients.
- Daily administration of captopril at a dosage of 37.5 mg.
- Regular monitoring of systolic and diastolic blood pressure, serum lipid levels (total cholesterol, triglycerides, lipoprotein cholesterol, apolipoproteins), and atherogenic index.
Main Results:
- Significant reductions in both systolic and diastolic blood pressure were observed throughout the 16-week treatment period (P < 0.001).
- No statistically significant changes were found in serum levels of total cholesterol, triglycerides, lipoprotein cholesterol, lipoprotein triglyceride, or apolipoproteins.
- The atherogenic index remained unchanged, although patients with initially high total cholesterol and low high-density lipoprotein cholesterol showed a trend toward improved lipid levels.
Conclusions:
- Captopril is effective in reducing blood pressure in hypertensive individuals.
- The study concludes that captopril does not adversely affect overall serum lipoprotein metabolism.
- Captopril may offer potential benefits for lipid profiles in specific patient populations with pre-existing dyslipidemia.
Abstract:
Captopril (37.5 mg daily) was administered to 64 hypertensive patients for 16 weeks. During treatment, systolic and diastolic blood pressures decreased significantly (from means of 164/98 mmHg before treatment to 150/90 mmHg at four weeks and 142/86 mmHg at eight weeks; P less than 0.001), but serum levels of total cholesterol, triglycerides, lipoprotein cholesterol, lipoprotein triglyceride, and apolipoproteins showed no significant changes. Scores on the atherogenic index did not change. Patients with high initial total cholesterol levels and low high-density lipoprotein cholesterol levels tended to improve their lipid levels. It is concluded that captopril does not adversely affect serum lipoprotein metabolism.